Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis

Author(s): Magnus Back

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 27 , 2009

Become EABM
Become Reviewer


The inflammatory environment within the atherosclerotic lesion stimulates the 5-lipoxygenase pathway of arachidonic acid metabolism, leading to the biosynthesis of the potent lipid inflammatory mediators leukotrienes. The present review summarizes the components of this pathway; the enzymes 5-lipoxygenase (5-LO, ALOX5) with its activating protein, FLAP (ALOX5AP), LTA4 hydrolase and LTC4 synthase, as well as the receptors for leukotriene B4 (BLT1 and BLT2) and cysteinyl-leukotrienes (CysLT1 and CysLT2), respectively. Genetic variations within the genes encoding these proteins have been associated with cardiovascular risk. Inhibiting the 5-lipoxygenase pathway through either leukotriene synthesis inhibitors or leukotriene receptor antagonists in experimental models of atherosclerosis has however generated contradictory results. Several inhibitors of the 5-lipoxygenase pathway are now evaluated in clinical trials of patients with cardiovascular disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [3116 - 3132]
Pages: 17
DOI: 10.2174/138161209789058020
Price: $65

Article Metrics

PDF: 19